Wednesday, 3 June 2026
  
Login

Australia's most trusted
source of pharma news

Wednesday, 03 June 2026
News

Who's signed this Sydney biotech?

Posted 3 June 2026 AM

Sydney-based Recce has announced a multi-million-dollar deal is in the works to license an anti-infective for sale across the Middle East and North Africa but is playing coy on who its partner is.

Recce has signed a non-binding term sheet for a ten-year exclusive distribution deal for R327G Topical Gel targeting Diabetic Foot Infections (DFI) for ten countries across the MENA region, with the finalised deal intended to be signed next quarter. It's the first distribution deal for the company, which has signed a couple of R&D deals with the US Army Institute of Surgical Research.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (1)

Sales & Customer Relations (18)

Clinical & Medical, R&D (5)

Regulatory, Pharmacovigilance & QA (2)

Other (8)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.